# A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

> **NCT01925274** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 19 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** PF-05212384
- **DRUG:** irinotecan
- **DRUG:** Cetuximab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01925274
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-15
- **Primary completion:** 2016-04-06
- **Final completion:** 2016-04-06
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no safety or efficacy issues that contributed to this decision.
- **Last updated:** 2019-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01925274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01925274, "A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01925274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*